Strata Critical Medical, Inc.
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
SRTA$6.05+8.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Interim
Unaudited Interim Condensed Consolidated Statements of Comprehensive Income (Loss)
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Net income (loss) | $2,154 | $(3,493) |
| Other comprehensive income (loss): | ||
| Foreign currency translation adjustments | — | 1,316 |
| Other comprehensive income | — | 1,316 |
| Comprehensive income (loss) | $2,154 | $(2,177) |
Unaudited Interim Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income · AccumulatedDeficit · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of January 1, 2026 | 86,702,183 | $7 | $424,616 | $— | $(145,551) | $279,072 |
| Issuance of common stock upon exercise of stock options | 286,960 | — | 52 | — | — | 52 |
| Issuance of common stock upon settlement of restricted stock units | 336,098 | — | — | — | — | — |
| Stock-based compensation - restricted stock | — | — | 5,035 | — | — | 5,035 |
| Shares withheld related to net share settlement | (128,337) | — | (582) | — | — | (582) |
| Retirement of common stock | (675,334) | — | — | — | — | — |
| Net income | — | — | — | — | 2,154 | 2,154 |
| Balance as of March 31, 2026 | 86,521,570 | $7 | $429,121 | $— | $(143,397) | $285,731 |
| Balance as of January 1, 2025 | 79,419,028 | $7 | $407,076 | $1,753 | $(186,898) | $221,938 |
| Issuance of common stock upon exercise of stock options | 1,568,167 | — | 60 | — | — | 60 |
| Issuance of common stock upon settlement of restricted stock units | 1,465,407 | — | — | — | — | — |
| Stock-based compensation - restricted stock | — | — | 4,217 | — | — | 4,217 |
| Shares withheld related to net share settlement | (1,478,968) | — | (4,306) | — | — | (4,306) |
| Other comprehensive income | — | — | — | 1,316 | — | 1,316 |
| Net loss | — | — | — | — | (3,493) | (3,493) |
| Balance as of March 31, 2025 | 80,973,634 | $7 | $407,047 | $3,069 | $(190,391) | $219,732 |
Unaudited Interim Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash Flows From Operating Activities: | ||
| Net income / (loss) | $2,154 | $(3,493) |
| Adjustments to reconcile net income (loss) to net cash and restricted cash used in operating activities: | ||
| Change in gain on sale of business | 344 | — |
| Depreciation and amortization | 3,060 | 1,697 |
| Stock-based compensation | 5,035 | 4,217 |
| Change in fair value of warrant liabilities | (1,459) | (2,752) |
| Change in fair value of other assets and liabilities | (3,444) | — |
| Accretion of interest income on held-to-maturity securities | (265) | (723) |
| Deferred tax expense | (77) | (17) |
| Other | 27 | 93 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 383 | 2,254 |
| Accounts receivable | 149 | (520) |
| Other non-current assets | 78 | 13 |
| Operating right-of-use assets/lease liabilities | 73 | (30) |
| Accounts payable and accrued expenses | (2,158) | (2,278) |
| Deferred revenue | (3) | 1,293 |
| Other | (12) | — |
| Net cash provided by/ (used in) operating activities (includes discontinued operations; see Note 4) | 3,885 | (246) |
| Cash Flows From Investing Activities: | ||
| Cash transfer related to sale of business | (290) | — |
| Capitalized software development costs | (302) | (532) |
| Purchase of property and equipment, net of proceeds from disposal | (5,179) | (2,614) |
| Purchase of held-to-maturity investments | — | (84,197) |
| Proceeds from maturities of held-to-maturity investments | 30,500 | 107,750 |
| Net cash provided by investing activities (includes discontinued operations; see Note 4) | 24,729 | 20,407 |
| Cash Flows From Financing Activities: | ||
| Proceeds from the exercise of common stock options | 52 | 60 |
| Taxes paid related to net share settlement of equity awards | (582) | (4,306) |
| Payments for debt issuance costs | (329) | — |
| Net cash used in financing activities (includes discontinued operations; see Note 4) | (859) | (4,246) |
| Effect of foreign exchange rate changes on cash balances | — | 126 |
| Net increase in cash and cash equivalents and restricted cash | 27,755 | 16,041 |
| Cash and cash equivalents and restricted cash - beginning | 31,232 | 19,647 |
| Cash and cash equivalents and restricted cash - ending | $58,987 | $35,688 |
| Reconciliation to consolidated balance sheets (includes discontinued operations; see Note 4) | ||
| Cash and cash equivalents | $58,723 | $34,830 |
| Restricted cash | 264 | 858 |
| Total cash and cash equivalents and restricted cash | $58,987 | $35,688 |
| Supplemental cash flow information | ||
| Non-cash investing and financing activities: | ||
| New leases under ASC 842 entered into during the period | $1,317 | $608 |
| Purchases of property and equipment and capitalized software in accounts payable and accrued expenses | 161 | 339 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.